Vivus Inc. (NASDAQ: VVUS) shares jumped on Wednesday after the company announced a crucial approval by the U.S. Food and Drug Administration (FDA). Specifically, the FDA approved the company’s supplemental New Drug Application (sNDA) for an improved formulation of Pancreaze. Vivus Inc : VVUS Stock Price Quote at Ally Invest Free current stock price quotes and data for Vivus Inc (VVUS). Research news, charts, stock market performance and earnings. Latest alteration:: VIVUS, Inc., (NASDAQ: VVUS ...
VVUS: VIVUS, Inc. - Earnings Announcements. Stay up to date with lastest Earnings Announcements for VIVUS, Inc. from Zacks Investment Research
Is VIVUS, Inc. (VVUS) Stock About to Get Hot Wednesday ... Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available. What's Happening With VVUS Stock Today? VIVUS, Inc. (VVUS) stock is trading at $3.76 as of 11:09 AM on Wednesday, Feb 5, a gain of $1.46, or 63.48% from the previous closing price of $2.30. VIVUS, Inc. (VVUS) Stock Price, Quote, History & News ... VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 7,218,750 shares of the Company’s common stock, at a purchase price of $1.60 per share, in a registered direct offering VVUS VIVUS, Inc. Stock Quote - FINVIZ.com VIVUS, Inc. operates as a specialty pharmaceutical company primarily in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body-mass index of 30 or greater (obese patients) or 27 or greater (overweight patients) in
View VIVUS's (NASDAQ:VVUS) earnings history, next earnings date and earnings forecasts from MarketBeat - Stock Market News and Research Tools logo.
VVUS - Vivus Stock Earnings Estimates - Barchart.com Earnings Estimates are available only for US equities. Earnings Surprises. The first table on the Estimates page compares Actual vs. Estimated earnings for the last four quarters. This table is designed to uncover Earnings Surprises — times when a stock's earnings either out-perform or under-perform the analysts' expectations. Typically, when VIVUS (NASDAQ:VVUS) Announces Earnings Results - Riverton Roll VIVUS (NASDAQ:VVUS) issued its earnings results on Tuesday. The biopharmaceutical company reported ($0.61) EPS for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.07, MarketWatch Earnings reports. The firm had revenue of $17.25 million during the quarter, compared to analysts’ expectations of $19.28 million. VVUS stock opened at $1.76 on Friday. The company has […]
1 Apr 2020 Shares of biopharma company VIVUS, Inc. (NASDAQ: VVUS) are skyrocketing following an announcement concerning launch plans for
Stock analysis for VIVUS Inc (VVUS:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. VIVUS Inc. Stock Price (VVUS) | Barron's View today's stock price, news and analysis for VIVUS Inc. (VVUS). Barron's also provides information on historical stock ratings, target prices, company earnings, market valuation and more. VVUS | VIVUS Inc. Stock Price & News - WSJ The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations VIVUS Earnings Release Date - VVUS | StocksEarning.com Proceed with caution. Strategy has degree of success but there are no guarantees. Ideally the options for VVUS will expire worthless. But if the VVUS stock falls to your strike price, you then need to buy the stock. This strategy for VVUS is independent from the Fast Money Trader (1-Day Hold) and Weekly Winners (7-Day Hold) strategies.
Find the latest VIVUS, Inc. (VVUS) stock quote, history, news and other vital information to help you with your stock trading and investing.
7 days ago · Looking into the profitability ratios of VVUS stock, an investor will find its ROE, ROA, ROI standing at 54.30%, -12.40% and -6.40%, respectively. Earnings per Share Details of VIVUS, Inc.: The E-P-S of VVUS is strolling at -2.96, counting Earning per Share growth this year at 14.90%. As a result, the company has an earning per share growth of EarningsWhispers - Investors Sign Up The Earnings Whisper Grade identifies where a stock is in the Earnings Expectation Life Cycle with the A+'s being in the Positive Earnings stage and, on average, gaining 7.33% from two days following the earnings release until the close just before its next earnings release - outperforming the overall stock market by 263%. Stocks with an Lowest Cost, Highest Growth:: VIVUS, Inc., (NASDAQ: VVUS ...